J
Jacqueline M. O'Connor
Publications - 4
Citations - 3636
Jacqueline M. O'Connor is an academic researcher. The author has contributed to research in topics: In vivo & Biological activity. The author has an hindex of 4, co-authored 4 publications receiving 3458 citations.
Papers
More filters
Journal ArticleDOI
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf,Steven W. Elmore,Alexander R. Shoemaker,Robert C. Armstrong,David J. Augeri,Barbara A. Belli,Milan Bruncko,Thomas L. Deckwerth,Jürgen Dinges,Philip J. Hajduk,Mary K. Joseph,Shinichi Kitada,Stanley J. Korsmeyer,Stanley J. Korsmeyer,Kunzer Aaron R,Anthony Letai,Chi Li,Michael J. Mitten,David G. Nettesheim,Shi Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Anatol Oleksijew,Andrew M. Petros,John C. Reed,Wang Shen,Stephen K. Tahir,Craig B. Thompson,Kevin J. Tomaselli,Baole Wang,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg +33 more
TL;DR: Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Journal ArticleDOI
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Alex R. Shoemaker,Michael J. Mitten,Jessica Adickes,Scott L. Ackler,Marion Refici,Debra Ferguson,Anatol Oleksijew,Jacqueline M. O'Connor,Baole Wang,David Frost,Joy Bauch,Kennan C. Marsh,Steven K. Tahir,Xiufen Yang,Christin Tse,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent, and ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials.
Journal ArticleDOI
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo
Alex R. Shoemaker,Anatol Oleksijew,Joy Bauch,Barbara A. Belli,Tony Borre,Milan Bruncko,Thomas Deckwirth,David Frost,Ken Jarvis,Mary K. Joseph,Kennan C. Marsh,Mcclellan William J,Hugh N. Nellans,Shi-Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Tilman Oltersdorf,Weiguo Qing,Wang Shen,Jason Stavropoulos,Stephen K. Tahir,Baole Wang,Robert B. Warner,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +26 more
TL;DR: A-385358 enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents (pac litaxel, etoposide, cisplatin, and doxorubicin) in several tumor cell lines and potentiates the activity of paclitaxel in vivo.
Journal ArticleDOI
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Debra Ferguson,Luis E. Rodriguez,Joann P. Palma,Marion Refici,Kenneth Jarvis,Jacqueline M. O'Connor,Gerard M. Sullivan,David Frost,Kennan C. Marsh,Joy Bauch,Haiying Zhang,Nan-Horng Lin,Saul H. Rosenberg,Hing L. Sham,Ingrid B.J.K. Joseph +14 more
TL;DR: Overall, ABT-100 has an acceptable pharmacokinetic profile, is well tolerated, and possesses broad-spectrum antitumor activity against a series of xenograft models similar to farnesyltransferase inhibitors in clinical development; therefore, it is an attractive candidate for clinical evaluation.